Britain and America have announced a key bilateral deal that will guarantee no levies on British pharmaceutical exports being sold in the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost funding on drugs through the National Health Service (NHS). This move guarantees that duties on these key goods will be held at zero for a timeframe of 36 months.
This agreement follows recent statements to significantly raise duties on patented drug products, with figures floated reaching double the cost.
"This deal between the United Kingdom strengthens the international landscape for cutting-edge drugs and brings long-overdue equity to transatlantic medicine commerce," a release said.
Economic Impact
Pharmaceuticals constitute one of the Britain's most significant exports to the America, which is clearly the largest buyer for leading UK drugmakers.
Export figures indicate that in the year to the end of September, the UK exported pharmaceutical products worth £11.1bn to the US. This value made up 17.4% of all goods exports in that timeframe.
"This deal safeguards employment, increases funding and facilitates the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.
Detailed UK Commitments
The pact involves several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to increase overall public funding on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. Previously, refunds exceeded 20%.
Broader Context
This agreement follows a ongoing row between the pharmaceutical industry and the UK government over drug pricing and approval rates.
These tensions were intensified by assertions that American customers were paying a premium for the identical medicines than people in the UK and Europe.
Recently, several major manufacturing plans in the UK have been halted or scrapped, while substantial expansions have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its budget allocation on drugs had shrunk as a share of its total funding over the previous ten-year period.
